The work of pharmaceutical researcher and consultant Robert Hindes, MD, includes clinical trials for medications to treat hepatitis and influenza. In collaboration with other experts, Robert Hindes, MD, recently appeared in the Journal of Hepatology for his research on the Hepatitis B drug entecavir.
Over 36 months, Hindes and other researchers studied patients with hepatitis B. After being treated with entecavir, patients received biopsies in order to gauge their progress. Results showed that more than 95 percent of the patients experienced histological improvement. The study concluded that use of entecavir produces a long-term reduction of fibrosis and cirrhosis.
In addition to conducting clinical trials regarding entecavir to treat hepatitis B, Dr. Hindes co-authored articles in The Lancet Infectious Diseases showing that the Hepatitis C drug sofosbuvir was proven effective in treating hepatitis C virus genotypes 1-3. These new interferon-free oral medications are part of an effort for researchers to increase the number of Americans cured of hepatitis. Over 90% of patients treated with sofosbuvir are cured of hepatitis C. Current treatments for Hepatitis B are very effective in suppressing the virus, but eradication of the Hepatitis B virus is much more difficult.
Over 36 months, Hindes and other researchers studied patients with hepatitis B. After being treated with entecavir, patients received biopsies in order to gauge their progress. Results showed that more than 95 percent of the patients experienced histological improvement. The study concluded that use of entecavir produces a long-term reduction of fibrosis and cirrhosis.
In addition to conducting clinical trials regarding entecavir to treat hepatitis B, Dr. Hindes co-authored articles in The Lancet Infectious Diseases showing that the Hepatitis C drug sofosbuvir was proven effective in treating hepatitis C virus genotypes 1-3. These new interferon-free oral medications are part of an effort for researchers to increase the number of Americans cured of hepatitis. Over 90% of patients treated with sofosbuvir are cured of hepatitis C. Current treatments for Hepatitis B are very effective in suppressing the virus, but eradication of the Hepatitis B virus is much more difficult.